(Q38067005)

28 August 2017

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial (English)

1 reference

28 August 2017

phase III clinical trial

0 references

author

Martine Piccart-Gebhart

12

object named as

Martine Piccart-Gebhart

0 references

Miguel Martin

object named as

Miguel Martin

10

0 references

Bent Ejlertsen

4

object named as

Bent Ejlertsen

1 reference

28 August 2017

3

Joyce O'Shaughnessy

1 reference

28 August 2017

11

Beverly Moy

1 reference

28 August 2017

7

Aman U Buzdar

1 reference

28 August 2017

Paul E Goss

1

1 reference

28 August 2017

Ian E Smith

2

1 reference

28 August 2017

Manfred Kaufmann

5

1 reference

28 August 2017

Frances Boyle

6

1 reference

28 August 2017

Pierre Fumoleau

8

1 reference

28 August 2017

William Gradishar

9

1 reference

28 August 2017

Kathleen I Pritchard

13

1 reference

28 August 2017

Deborah Lindquist

14

1 reference

28 August 2017

Yanin Chavarri-Guerra

15

1 reference

28 August 2017

Gursel Aktan

16

1 reference

28 August 2017

Erica Rappold

17

1 reference

28 August 2017

Lisa S Williams

18

1 reference

28 August 2017

Dianne M Finkelstein

19

1 reference

28 August 2017

TEACH investigators

20

1 reference

28 August 2017

10 December 2012

1 reference

Lancet Oncology Commission

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

1

1 reference

28 August 2017

88-96

1 reference

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Trastuzumab containing regimens for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Breast cancer in Brazil: present status and future goals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970508-9

7 January 2021

10.1016/S1470-2045(12)70508-9

Identifiers

DOI

1 reference

28 August 2017

1 reference